Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BIO.B
BIO.B logo

BIO.B Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
296.490
Open
297.370
VWAP
296.49
Vol
--
Mkt Cap
7.93B
Low
296.490
Amount
--
EV/EBITDA(TTM)
18.40
Total Shares
26.76M
EV
7.54B
EV/OCF(TTM)
14.78
P/S(TTM)
3.08
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Show More

Events Timeline

(ET)
2025-08-01
10:00:09
Bio-Rad rises 15.8%
select
2025-07-31 (ET)
2025-07-31
16:28:26
Bio-Rad sees FY25 non-GAAP, currency-neutral revenue growth of flat to up 1%
select
2025-07-31
16:27:21
Bio-Rad reports Q2 adjusted EPS $2.61, consensus $1.75
select
2025-07-07 (ET)
2025-07-07
09:23:59
Bio-Rad expands digital PCR offering with new platforms
select

News

moomoo
2.0
04-21moomoo
NYSE Suspends Trading of Bio-Rad Labs B; Additional Information Listed at $277.00
  • Company Overview: NYSE HALT BIORAD LABS is a significant player in the biotechnology sector, focusing on innovative solutions and products.

  • Financial Status: The company has reported a substantial financial figure of $277,000,000, indicating strong market performance or investment potential.

Barron's
4.5
02-13Barron's
S&P 500 Futures Decline in Pre-Market Trading; Pinterest and Bio-Rad Labs Underperform
  • Rivian Automotive Performance: Rivian Automotive Inc. Cl A (RIVN) saw a significant increase of 20.4% in pre-market trading.
  • Roku Inc. Performance: Roku Inc. Cl A (ROKU) experienced a rise of 15.3% in pre-market trading.
  • Market Context: The U.S. stock markets are set to open in two hours, indicating potential volatility.
  • Investor Sentiment: The pre-market gains for both companies suggest positive investor sentiment ahead of the market opening.
TipRanks
4.0
2025-11-25TipRanks
3 Stocks Signaling 'Buy' Opportunities for Investors Based on Technical Analysis
  • Market Volatility and Technical Analysis: Amid market fluctuations, investors can leverage technical analysis to identify promising stock opportunities, with TipRanks highlighting Wintrust Financial, Bio-Rad Laboratories, and Agree Realty as Strong Buy candidates.

  • Wintrust Financial Overview: Wintrust Financial is experiencing an upward trend, supported by a Strong Buy rating and 12 bullish signals indicating strong momentum according to TipRanks’ technical analysis.

  • Bio-Rad Laboratories Insights: Bio-Rad Laboratories also holds a Strong Buy consensus, with a positive Rate of Change (ROC) of 1.69, suggesting upward momentum and a Buy signal for the stock.

  • Agree Realty Corporation Analysis: Agree Realty is rated a Strong Buy based on moving average consensus, with a positive ROC of 2.75, indicating strong upward momentum and a favorable Buy signal.

Yahoo Finance
9.5
2025-10-30Yahoo Finance
Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue
  • Earnings Report: Bio-Rad Laboratories (BIO) announced Q3 non-GAAP earnings of $2.26 per diluted share.
  • Access Requirement: Users need to sign in to access their portfolio information.
NASDAQ.COM
4.0
2025-10-23NASDAQ.COM
BIO Surpasses Average Analyst Expectations
  • Current Stock Performance: Bio-Rad Laboratories Inc's shares have surpassed the average analyst 12-month target price of $331.40, trading at $333.97/share, prompting potential analyst reactions regarding valuation adjustments.

  • Analyst Target Range: Within the Zacks coverage universe, analyst targets for Bio-Rad vary significantly, with one analyst setting a low target of $265.00 and another as high as $437.00, indicating a standard deviation of $68.171.

  • Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on a trajectory towards higher targets or if it has become overvalued, suggesting a potential need to reassess their positions.

  • Analyst Ratings Overview: The article references a rating scale from 1 (Strong Buy) to 5 (Strong Sell) for Bio-Rad, reflecting the collective insights of analysts covering the company.

Newsfilter
9.5
2025-10-16Newsfilter
Bio-Rad Scheduled to Release Q3 2025 Financial Results on Wednesday, October 29, 2025
  • Financial Results Announcement: Bio-Rad Laboratories will report its Q3 2025 financial results on October 29, 2025, after market close, followed by a conference call at 2:00 PM PT.

  • Participation Details: Interested parties can join the conference call by dialing specific numbers or accessing a live webcast available on the company's Investor Relations website.

Wall Street analysts forecast BIO.B stock price to rise
0 Analyst Rating
Wall Street analysts forecast BIO.B stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for Bio Rad Laboratories Inc (BIO.B.N) is 33.56, compared to its 5-year average forward P/E of 30.07. For a more detailed relative valuation and DCF analysis to assess Bio Rad Laboratories Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
30.07
Current PE
33.56
Overvalued PE
32.82
Undervalued PE
27.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
18.90
Current EV/EBITDA
33.72
Overvalued EV/EBITDA
25.56
Undervalued EV/EBITDA
12.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.12
Current PS
3.01
Overvalued PS
3.47
Undervalued PS
2.76

Financials

AI Analysis
Annual
Quarterly

Whales Holding BIO.B

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Bio Rad Laboratories Inc (BIO.B) stock price today?

The current price of BIO.B is 296.49 USD — it has increased 0

What is Bio Rad Laboratories Inc (BIO.B)'s business?

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

What is the price predicton of BIO.B Stock?

Wall Street analysts forecast BIO.B stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO.B is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Bio Rad Laboratories Inc (BIO.B)'s revenue for the last quarter?

Bio Rad Laboratories Inc revenue for the last quarter amounts to 592.10M USD, increased 1.14

What is Bio Rad Laboratories Inc (BIO.B)'s earnings per share (EPS) for the last quarter?

Bio Rad Laboratories Inc. EPS for the last quarter amounts to -19.55 USD, decreased -953.71

How many employees does Bio Rad Laboratories Inc (BIO.B). have?

Bio Rad Laboratories Inc (BIO.B) has 7450 emplpoyees as of July 08 2026.

What is Bio Rad Laboratories Inc (BIO.B) market cap?

Today BIO.B has the market capitalization of 7.93B USD.